

As A Specialty Pharma Company, Global Health Ventures, Inc. Finds A Faster Path To The Market For Their Products By Taking FDA Approved Drugs That Have Expired Patents And Reformulating Them, Making Their Delivery Much Faster Through The Blood With Lower Side-Effects

**Healthcare
Drug Delivery
(GHLV-OTC: BB)**

**Global Health Ventures, Inc.
409 Granville Street, Suite # 1023
Vancouver British Columbia V6C 1T2
Tel: 604-324-4844
Fax: 604-324-4845
Toll Free: 1-877-448-4620**



**Dr. Hassan Salari, Ph.D.
Chairman, President
CEO and Director**

BIO:

Salari is an experienced health care executive with over 20 years of involvement in managing private and publicly traded pharmaceutical companies in North America. Having been the founder and President & CEO of Chemokine Therapeutics from July 1998 to May 2007, Dr. Salari raised over \$40 million for the Company, and has made the public listing of the company on the Toronto Stock Exchange as well as Over the Counter Bulletin Board in the United States. Dr. Salari also founded and built the biotechnology company, Inflazyme Pharmaceuticals from 1992 to 1998 and brought the Company public on the Toronto Stock Exchange. His role as President and

Chief Executive Officer of Inflazyme Pharmaceuticals included managing its international business affairs. He raised over \$30 million for Inflazyme on the public stock market. Dr. Salari was the founding director of Pacgen Biopharma, a publically traded company on the Toronto Stock Exchange Venture Board from December 2006-December 2008. Dr. Salari is also the founder and president of Posh Cosmeceuticals, a specialized cosmetic company with operations in Canada. He is a founding investor of Pacific Therapeutics, a Vancouver based biotechnology company with emphasis in pulmonary diseases. He is the Founder and Chairman of the Board of Neurokine Pharmaceuticals, a publicly listed Pharmaceutical company in Canada developing new drugs for neurological disease, including Alzheimers diseases.

Previous to his entrepreneurial ventures, Dr. Salari served as consultant and advisor to Merck, Beecham (now "Glaxo"), Rhone Poulenc (now "Sanofi-Avantis"), Upjohn (now "Pfizer"), Beafour-Ipsen (now "Ipsen") and Zymogenetics.

Company Profile:

Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drug. The company is currently developing a number of sublingual formulation of FDA approved drugs. The com-

pany's lead product is X-Excite. In experimental studies, X-Excite has been shown to reach blood stream rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. X-Excite is presently in clinical trials in Europe. The Company also uses the same technology to deliver a vast number of other FDA approved drugs where they are needed to act rapidly. These include, stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies.

Interview by: Lynn Fosse, Sr. Editor

CEOCFO: Dr. Salari, what is the main focus of Global Health Ventures?

Dr. Salari: Global Health Ventures is a specialty pharma, which means that we take drugs that are coming off the patent, reformulate them and we file a patent. This gives us another 20 years of exclusivity and market intellectual property for a product. We have developed a number of products and our formulation makes drugs to be delivered much faster through the blood with lower side-effects.

CEOCFO: What types of problems are you looking to address?

Dr. Salari: We look at the problems with the drugs or what we want to see for the drugs. For example, one of our drugs, which we call X-Excite, is a drug used for sexual enhancement and erectile dysfunction. The current formulation is oral delivery of the same drug, which takes about an hour to an hour and half to reach a good level in the blood. We have reformulated it to be delivered under the

tongue, which would be very rapid, in five to ten minutes. In addition, because it doesn't go to the stomach, mostly then you don't have some of the side-effects associated with the stomach break-down and liver break-down, and intestinal breakdown. So really you are reformulating a drug that will work very fast so you don't need to wait and there are very less side-effects. Another drug we are working with I cannot give you the name because it is proprietary, but it is a drug which is again used vastly throughout the world, it affects heart rate and blood pressure and we have reformulated it. We used a very tiny amount and it rapidly gets into the blood and it is basically works as an anti-anxiety and anti-stress, so it basically relaxes the body. We have a formulation of nicotine, which again is small tiny pills and you put it under the tongue and in two or three minutes it is in the blood and the people don't have craving for cigarettes. We have energy-boosting products that if you are tired or you have exercised for a long time you can put the tiny pill on the tongue and it helps to boost your energy.

CEO CFO: Can any substance be made to go under the tongue, and what does Global Health know about doing this that others do not?

Dr. Salari: It is a proprietary formulation, so we have developed the formulation and patented it. What does it do? Ordinary drugs if you put them under the tongue they will not pass through the skin because they are either large in size or they cannot stick to the skin. So what we have put in this formulation is something that is perfectly fine, approved by FDA, and vastly used as a food additive in other products. It actually causes the dilation of the tubes or the pores increased permeability, so it makes it easier to penetrate the tissue and skin.

CEO CFO: Is this a method of delivery that has been accepted by the medical community?

Dr. Salari: Yes and there are some medicines already that deliver under the tongue. For example, nitro glycerin for the heart attack or angina, when you put it under the tongue it goes rapidly to the blood. Nitrate is small in size and has its

own property of sticking and going through the traffic, so as water comes out it goes up. So they really made other drugs that similarly and accepted. We had to do the test in humans with a lower dosage, because if you take the drug as a pill or a tablet, it goes to your stomach, and only 20% to 50% goes to the blood. However, if you put it under the tongue, where 80% goes to the blood, well that means your dosage has to be significantly smaller. This is good because you spend less money on the drug.

CEO CFO: Where are you in development?

Dr. Salari: We are in clinical testing as I mentioned in Europe right now under the European guidelines, because it is easier and cheaper. We plan to do clinical trials in the United States next year (2011) and we think the trials will go very fast, maybe twelve months. Once the trials are finished, we can start signing marketing

Global Health Ventures is a specialty pharma, which means that we take drugs that are coming off the patent, reformulate them and we file a patent. This gives us another 20 years of exclusivity and market intellectual property for a product. We have developed a number of products and our formulation makes drugs to be delivered much faster through the blood with lower side-effects. - Dr. Hassan Salari, Ph.D.

partners.

CEO CFO: What is the financial picture like today for Global Health Ventures?

Dr. Salari: The development is expensive, but we have a signed \$20 million equity deal with Lincoln Park Capital in Chicago. So as we require the money we take out from the equity line and we finance the company. Therefore, the financial situation is good and we use it to develop product, but also as soon as the first product in development is finished we will start making deals to generate income.

CEO CFO: Development and commercialization are two different focuses, how will Global Health handle the next phase?

Dr. Salari: Global Health Ventures is actually very strong in drug development and getting approval. I have been involved in four or five pharmaceutical and

biotech companies and I made some of them very big. There are other people with me that are also very experienced. We presently do not have a marketing department and we don't have a marketing ability, so we don't plan to sell the products ourselves. We plan to go with companies that have marketing muscle and knowledge such as Glaxo, Pfizer or Lilly.

CEO CFO: In closing, why should potential investors pay attention to Global Health Ventures?

Dr. Salari: They should look at Global Health Ventures for the following reasons. First, there are many products that are coming off the patent and the companies that are already selling a brand will lose 90% of their revenue. By creating a new formulation, they can maintain significant portion of the market. So they will be comfortable to deal with us to take the product off our hands. The second

reason is that this technology could apply to other drugs and there are many drugs that need to work fast, such as antidepressants. Asthma drugs and allergy drugs need to work fast, because if you have an allergy to bee stings and you get one, currently, you either can carry a needle with a shot of adrenaline or some drugs that take time in which you can suffer or

even die. However, we can provide the opportunity to quickly put this little pill under your tongue. So there is tremendous need for something to work fast, cheap and easy to carry, because you cannot carry a needles and syringes in an airplane, but you can carry a couple of little pills on with you. The third reason is that we work with drugs that have already been approved by the FDA. So the risk is very little, because you know how a drug works, you know how nicotine works, so you are not worried about an unknown drug, not knowing what it will do. So we are working with a known product, but new applications, new delivery systems. It is a very safe approach, so the investors risk is much lower with Global Health rather than an exotic company where you may not know whether the product will work, and even if it does work, if it is going to have some nasty side-effects.